capture2

Linked BLUEPRINT epigenetics project delivers beyond expectation

BLUEPRINT was officially launched on 1 October 2011. With the principal funding of €30 million by the European Union the project has been the European cornerstone of the international research cooperation effort International Human Epigenome Consortium, bringing together organisations and researchers from across the globe. Involving 42 leading European universities, research institutes, small and medium-sized enterprises (SMEs) and industry partners from 12 countries, BLUEPRINT focused on the epigenetic states of cells in blood because this tissue is relevant to many human diseases from cancers to autoimmune diseases such as diabetes. Together, blood diseases affect millions of people worldwide.

“Our BLUEPRINT results have important implications for our understanding of biology and, importantly, for novel therapeutic development,” says Henk Stunnenberg. “Epigenetics plays a crucial role in cell and embryo development, but also defines what constitutes a ‘good’ cell and clarifies a person’s individual disease. The results are truly a blueprint for biology and medicine. Moreover, the industrial partners involved in the project have contributed to the development of smart technologies.”

Press release: http://www.blueprint-epigenome.eu/UserFiles/file/Meetings/meeting%20Brussels/BLUEPRINT_Media_Kit_Press_Release.pdf

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.